Characterization of the Global Metabolic Profile of Canagliflozin in Rat Plasma, Urine and Feces Based on HPLCUV-MS Analysis


Rawa Akasha, Abdul Wahab Allaf, Mohammad Amer Al-Mardini

Published in

Research Journal of Pharmacy and Technology, Volume 13, Issue 1, January 2020.


Canagliflozin is a newly approved drug for type II diabetes mellitus, in the present work, a strategy based on high performance liquid chromatography combined with mass spectrometry (HPLC-UV/MS) method was proposed to systematically characterize the in vivo metabolites of canagliflozin in Rats. After oral administration of Canagliflozin to rats in a single dose of 3mg/kg, the rat plasma, urine, feces samples were collected and used in order to to determine metabolites. As a result of that and besides the parent drug, a total of 12 metabolites of canagliflozin were detected and was indicated that the metabolic pathways of canagliflozin in rats included: oxidation (as a main rout), glucuronation, and hydroxylation The result could provide valuable information regarding the metabolism of canagliflozin in rats, which contribute to better understanding of its action mechanism.

Keywords: canagliflozin; metabolites; diabetes; HPLC-UV/MS; sodium glucose co‐transporter 2 inhibitor.

Link to abstract